RxPONDER clinical trial key findings
presented at San Antonio Breast Cancer Symposium
December 8-11, 2020
The majority of postmenopausal HR+, HER2-, N1 patients can be spared chemotherapy when decisions are guided with the Oncotype DX®test
RxPONDER clinical trial key findings*
- The majority of postmenopausal HR+, HER2-, N1 patients can be spared chemotherapy when decisions are guided with the Oncotype DX test
- Postmenopausal women with 1-3 positive nodes and Recurrence Score® results 0-25 can forgo adjuvant chemotherapy regardless of clinical pathological parameters
- Premenopausal women with 1-3 positive nodes and Recurrence Score® results 0-25 significantly benefit from chemotherapy
- RxPONDER study results are expected to be practice-changing for postmenopausal N1 HR+, HER2-, early breast cancer patients
* Kalinsky et al. San Antonio Breast Cancer Symposium 2020, GS3-00
RxPONDER clinical trial design
- RxPONDER, independently led by the SWOG Cancer Research Network, is one of the largest clinical trials for patients with HR+, HER2- early breast cancer and N1 disease
- The trial was designed to determine the effect of chemotherapy, if any, in patients who had a Recurrence Score® result 0-25
Exact Sciences Lunch Symposium
Yes or No? Answering chemotherapy and endocrine therapy questions through a case-based discussion with the Oncotype DX test
Speakers
Alison Stopeck, MD
Stony Brook Cancer Center
Jeremy Force, DO
Duke Cancer Center
Christy Russell, MD
Exact Sciences
This Exhibitor Product Theatre is a promotional activity and is not approved for continuing education credit. The content of this Exhibitor Product Theatre and opinions expressed by presenters are those of the sponsor or presenter and are not those of the San Antonio Breast Cancer Symposium® (SABCS®).
This Exhibitor Product Theatre is a promotional activity and is not approved for continuing education credit. The content of this Exhibitor Product Theatre and opinions expressed by presenters are those of the sponsor or presenter and are not those of the San Antonio Breast Cancer Symposium® (SABCS®).